Luminary Therapeutics

Founded in 2019 and based in Minneapolis, Minnesota, Luminary Therapeutics is dedicated to pioneering non-viral cell therapies for cancer and autoimmune diseases. The company's core mission is to provide innovative allogeneic cell therapies that address the limitations of viral-based treatments. Utilizing their unique Gamma 2.0+ platform, Luminary focuses on developing therapies for solid tumors and B cell malignancies, aiming to increase access to treatment for underserved patient populations.

Luminary Therapeutics boasts a team of distinguished scientists and a robust scientific advisory board. The company has made significant strides in advancing its pipeline through pre-clinical and clinical stages, with notable achievements in early therapeutic discovery and Phase I clinical trials. By overcoming key challenges in the CAR T industry, Luminary is making a substantial impact on the field of cell therapy, offering promising new treatments for patients with difficult-to-treat cancers and autoimmune conditions.